Day: November 23, 2019

Selected Financial IndicatorsSummarized selected financial indicators of the Group for 9 months of 2019 compared to 9 months of 2018 and 30.09.2019 compared to 31.12.2018 were as follows:Financial performanceThe Group`s sales amounted to 44 811 thousand EUR during 9 months of 2019, representing a 10.1% decrease as compared to the same period of previous year. Overall, wholesales decreased by 14.3%, measured in EUR.The Group’s gross profit during 9 months of 2019 amounted to 22 657 thousand EUR and decrease by 20.4% compared to previous year. The gross margin during 9 months of 2019 decreased to 50.6%, from 57.1% in the respective period of previous year. The cost of sold goods increased by 3.7%.Consolidated operating profit for 9 months of 2019 amounted to 10 090 thousand EUR, compared to 15 926 thousand EUR in 9 months of 2018, decrease...

Põhilised finantsnäitajadKontserni 2019. aasta 9 kuu (võrrelduna 2018. aasta 9 kuuga) ja 30.09.2019 (võrrelduna 31.12.2018) põhilised finantsnäitajad on järgmised:MajandustulemusedKontserni 2019. aasta 9 kuu käive moodustas 44 811 tuhat eurot, langus eelmise aasta sama perioodiga võrreldes on 10,1%. Hulgimüügi käive vähenes 14,3% võrra, mõõdetuna eurodes.Kontserni 2019. aasta 9 kuu brutokasum oli 22 657 tuhat eurot, vähenedes eelmise aastaga võrreldes 20,4%. Perioodi brutokasumi marginaal vähenes 2019. aasta 9 kuu jooksul 57,1%-lt 50,6%-le. Müüdud toodangu kulu kasvas 3,7% võrra.2019. aasta 9 kuu konsolideeritud ärikasum vähenes 36,6% ja ulatus 10 090 tuhande euroni võrreldes 2018. aasta 9 kuu konsolideeritud ärikasumiga summas 15 926 tuhat eurot. 2019. aasta 9 kuu ärikasumi rentaablus oli 22,5% võrreldes 32,0%-ga eelmise aasta samal...

– Controlled IL-12 evaluated as monotherapy in an expanded number of patients reinforced favorable safety profile and initial data consistent with immune-mediated anti-tumor effects –– Controlled IL-12 can be combined with full dose of a PD-1 inhibitor; favorable safety profile and initial data consistent with immune-mediated anti-tumor effects –– Immune-mediated pseudoprogression followed by reduction in tumor burden observed in both monotherapy and combination studies with Controlled IL-12 –PHOENIX, Nov. 23, 2019 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq:ZIOP), today announced the presentation of new interim analyses of clinical data from two ongoing substudies in its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as monotherapy and in combination with a PD-1 inhibitor,...

CAMBRIDGE, Mass. and BEIJING, China, Nov. 23, 2019 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced preliminary clinical data from a Phase 2 clinical trial of its investigational anti-PD-1 antibody tislelizumab in combination with chemotherapy in patients with gastric/ gastroesophageal junction (G/GEJ) adenocarcinoma or esophageal squamous cell carcinoma (ESCC) that were presented in a poster at the European Society for Medical Oncology (ESMO) Asia 2019 Congress in Singapore.“In this trial, the combination treatment of tislelizumab and chemotherapy demonstrated durable responses and was generally well-tolerated in patients with G/GEJ...

Vancouver, British Columbia, Nov. 22, 2019 (GLOBE NEWSWIRE) — Draganfly Inc. (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading systems developer within the commercial Unmanned Aerial Vehicle (“UAV”) and the Unmanned Vehicle Systems (“UVS”) space, is pleased to be a part of the Levis Trophy Truck Team Driven by Ryan Arciero alongside Levis, Seaspan ULC, and BN3TH apparel at the Baja 1000. The Baja 1000 is held annually in November on the Baja Peninsula and covers 800.5 miles of grueling course. Traditionally it is hard to track the vehicles on foot or by car and as a result, the teams have relied on the use of helicopters for their aerial filming and medical support.“This is off-road racing’s oldest and most prestigious competition and we’re honored to be a part of such a winning team. Starting...

VANCOUVER, British Columbia, Nov. 22, 2019 (GLOBE NEWSWIRE) — RevoluGROUP Canada Inc. (TSX-V: REVO) (“the Company”) would like to clarify the November 15, 2019 news release concerning the Definitive Agreement (“DA”) with RedCHAPINA S.A, signed on November 14th, 2019. After further analysis, the amount payable to RedCHAPINA, originally confirmed to be between $2.00 and $2.35 USD per individual beneficiary delivery into: Mexican, Salvadoran and Guatemalan territories, did not contemplate certain minor ancillary amounts. Therefore, the amount payable for said cash remittance deliveries could vary depending upon certain scenarios and, as such, the previously provided information was not accurate.RevoluVIP Integration of Cruises And Car RentalThe company would like to inform shareholders that legal counsel has formally remitted a letter...

LONDON, Nov. 23, 2019 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will share analyses from two clinical studies of savolitinib and fruquintinib at the fifth European Society for Medical Oncology Asia Congress (“ESMO Asia”) on November 22 to 24, 2019 in Singapore.Savolitinib: the TATTON study was selected as a late-breaking presentation in the Presidential Session at ESMO Asia.Earlier results of this study (cut-off date of August 31, 2017) were first presented on October 17, 2017 at the World Conference on Lung Cancer (WCLC).1  Interim results from this study (cut-off date of February 28, 2018) were presented on March 31, 2019 at the American Association of Cancer Research (AACR) Annual Meeting2 (clinicaltrials.gov identifier: NCT02143466). The TATTON trial supports SAVANNAH, an ongoing Phase...

VANCOUVER, British Columbia, Nov. 22, 2019 (GLOBE NEWSWIRE) — Prime Mining Corp. (TSX.V: PRYM) (OTCQB: EPWMF) (Frankfurt:04V3) (“Prime” or the “Company”) has been requested by OTC Markets Group Inc. (“OTC Markets”) to comment on recent promotional activity concerning its common shares traded on the OTCQB.On November 20, 2019, OTC Markets sent the Company copies of articles by Epic Stockpicks (Wolf of Penny Stocks) and Penny Stock Titans (Interactive Offers).  All are third party marketing and awareness firms utilized by IR Revolution Marketing Corp., which was retained by the Company to coordinate marketing materials and shareholder communications programs.  The Company only became aware of the articles on November 20, 2019, following notification by OTC Markets.The Company does not believe the statements referencing it in the articles...

(all in US$ unless otherwise noted)VANCOUVER, British Columbia, Nov. 22, 2019 (GLOBE NEWSWIRE) — Alio Gold Inc. (TSX, NYSE AMERICAN: ALO) (“Alio Gold” or the “Company”), is pleased to announce that a settlement agreement (the “Agreement”) has been signed with Maverix Metals Inc. (“Maverix”) regarding disputed royalty payments at the Company’s Florida Canyon Mine. The Agreement clarifies the definition of “Allowable Deductions” in calculating the royalty, reduces the royalty amount to 3.0% from 3.25% and provides for a one-time payment by Alio Gold to Maverix of $300,000 in either cash or shares within one-year of closing.About Alio GoldAlio Gold is a gold mining company. We are focused on the safe and profitable production of gold from our cornerstone asset, the 100% owned Florida Canyon Mine in Nevada, USA. The Company also owns...